Conatus Pharmaceuticals Inc (CNAT) Stock Rating Reaffirmed by Aegis
Conatus Pharmaceuticals Inc (NASDAQ:CNAT)‘s stock had its “buy” rating reissued by research analysts at Aegis in a note issued to investors on Friday, May 5th. They presently have a $11.00 price objective on the biotechnology company’s stock. Aegis’ price target would indicate a potential upside of 101.47% from the company’s previous close.
CNAT has been the topic of several other research reports. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 14th. FBR & Co reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Conatus Pharmaceuticals in a research note on Wednesday, March 15th. Stifel Nicolaus reaffirmed a “buy” rating and set a $9.00 price objective (up previously from $7.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, March 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Conatus Pharmaceuticals in a research note on Friday, March 17th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $13.25.
Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) traded down 0.4670% during mid-day trading on Friday, hitting $5.4345. 197,422 shares of the company were exchanged. The company has a 50 day moving average of $6.85 and a 200 day moving average of $4.57. The company’s market capitalization is $142.22 million. Conatus Pharmaceuticals has a 52 week low of $1.45 and a 52 week high of $9.40.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.20. The business had revenue of $7 million during the quarter, compared to analyst estimates of $5.88 million. During the same quarter last year, the company posted ($0.35) EPS. Equities analysts anticipate that Conatus Pharmaceuticals will post ($0.83) earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. ING Groep NV bought a new position in Conatus Pharmaceuticals during the fourth quarter valued at approximately $110,000. Ellington Management Group LLC bought a new position in Conatus Pharmaceuticals during the fourth quarter valued at approximately $154,000. Courage Capital Management LLC bought a new position in Conatus Pharmaceuticals during the third quarter valued at approximately $200,000. Morgan Stanley raised its position in Conatus Pharmaceuticals by 265.6% in the first quarter. Morgan Stanley now owns 67,095 shares of the biotechnology company’s stock valued at $386,000 after buying an additional 48,741 shares in the last quarter. Finally, Nationwide Fund Advisors acquired a new stake in shares of Conatus Pharmaceuticals during the first quarter worth about $413,000. Institutional investors and hedge funds own 15.90% of the company’s stock.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Stock Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.